Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8663386 | 0.83 | SIGMAR1 (0.47) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL8429503 | 0.81 | KDM4E (0.64) | SIGMAR1DRD2KDM4ESMN1; SMN2HTR1A | |
| SCHEMBL8429501 | 0.81 | KDM4E (0.64) | SIGMAR1DRD2KDM4ESMN1; SMN2HTR1A | |
| Hydrochloric Acid SCHEMBL8428831 | 0.80 | KDM4E (0.66) | DRD2KDM4ESMN1; SMN2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL8428835 | 0.80 | KDM4E (0.66) | DRD2KDM4ESMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8427010 | 0.77 | KDM4E (0.62) | SIGMAR1DRD2KDM4ESMN1; SMN2DRD4 | |
| SCHEMBL8427008 | 0.77 | KDM4E (0.62) | SIGMAR1DRD2KDM4ESMN1; SMN2DRD4 | |
| SCHEMBL5242533 | 0.77 | SLC6A4 (0.53) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL28069755 | 0.76 | SIGMAR1 (0.55) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL12798134 | 0.76 | SIGMAR1 (0.55) | SIGMAR1DRD2HTR1AHTR2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| WO-2009061881-A1 | SPIRODIHYDROBENZOFURANS AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | SIGMAR1 315/4885DRD2 227/4885KDM4E 4250/4885 |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | SIGMAR1 315/4885DRD2 227/4885KDM4E 4250/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | SIGMAR1 734/4885DRD2 1630/4885KDM4E 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.